Men and women take the same doses of semaglutide and tirzepatide – dosing isn’t based on sex. But results are not identical. Clinical trial data consistently shows men lose a smaller percentage of body weight than women on the same medication, even though they often lose more total pounds. Here’s what actually differs, and why.
Key takeaways
- Dosing schedules for weight loss injections are identical for men and women – based on tolerability, not gender
- Women lose 4-8 percentage points more body weight than men on the same GLP-1 medication, per STEP trial data
- Men often lose more pounds overall because they typically start at a higher body weight
- A 2025 study found GLP-1 treatment normalized testosterone in men who had low levels at baseline
- Roughly 20-30% of weight lost is lean muscle mass – about the same ratio for men and women
- Tirzepatide (Zepbound, Mounjaro) generally outperforms semaglutide (Wegovy, Ozempic) for men, as it does for women
Do men and women take different doses of weight loss injections?
No. Semaglutide and tirzepatide use the exact same dose-escalation schedule regardless of sex. Semaglutide starts at 0.25mg weekly and titrates up to a maintenance dose of 1.7mg or 2.4mg. Tirzepatide starts at 2.5mg and can climb as high as 15mg, depending on how well a person tolerates each step.
Dose increases are timed around side effects, not gender. A provider raises the dose when nausea and GI symptoms are manageable, and holds it steady when they’re not. Body weight and BMI can factor into a provider’s starting recommendation, but there’s no separate “male dosing chart” in the FDA labeling for either drug.
Explore current options: weight loss prescriptions · Wegovy · Zepbound
How do weight loss results actually differ by sex?
They differ more than most men expect. Across the major semaglutide trials, women consistently lost a larger share of their body weight than men did on the same dose.
| Trial | Population | Women’s average loss | Men’s average loss |
|---|---|---|---|
| STEP 1 | Adults with obesity, no diabetes | 14.0% | 8.0% |
| STEP 2 | Adults with type 2 diabetes | 7.5% | 4.6% |
| STEP 4 | Maintenance after run-in period | 16.2% | 9.3% |
That’s not a small gap. In STEP 1, women lost nearly double the percentage of body weight that men did, on the same medication and the same dose. The pattern shows up across semaglutide, liraglutide, and dulaglutide, so it isn’t unique to one drug.
Why do men lose a lower percentage of weight than women?
The leading explanation is hormonal. Estrogen appears to work together with GLP-1 in the brain, amplifying its effect on appetite and food-motivated behavior. Research on GLP-1 receptor activity shows it’s more pronounced during the phases of the menstrual cycle when estrogen peaks – suggesting estrogen isn’t just along for the ride, it’s actively boosting how strongly the brain responds to these drugs.
Men, without that estrogen synergy, get a real but comparatively smaller appetite-suppressing signal from the same dose. It’s a biological difference in drug response, not a sign the medication is failing or that a man is doing something wrong.
Men often lose more pounds, even with a lower percentage
Percentages don’t tell the whole story. Men typically start GLP-1 treatment at a higher absolute body weight than women, so a smaller percentage loss can still mean more pounds on the scale. A man starting at 250 pounds who loses 9% is down 22.5 pounds – close to what a 180-pound woman loses at a 14% reduction (25.2 pounds), even though her percentage is much higher.
If you’re a man judging your own progress against numbers you’ve seen online, weigh yourself against your own trend line, not against a percentage benchmark that was largely built from mixed-sex trial averages.
Weight loss injections and testosterone
This is one of the more encouraging findings for men starting treatment. A retrospective study presented at ENDO 2025, following 110 men with obesity or type 2 diabetes over 18 months, found the share of men with normal total and free testosterone rose from 53% to 77% while on GLP-1 therapy. None of the men were on testosterone therapy at baseline.
GLP-1 drugs don’t act on testosterone receptors directly. The likely mechanism is indirect: obesity itself suppresses testosterone, largely by driving up inflammation and converting testosterone to estrogen in fat tissue. As GLP-1 therapy reduces fat mass, that suppression eases and testosterone tends to recover.
That said, the data has limits – it’s retrospective, not a controlled trial, and researchers didn’t track what happens to testosterone if the weight comes back. Men with symptoms of low testosterone (fatigue, low libido, reduced muscle strength) during treatment should get levels checked rather than assume it will self-correct. Testosterone therapy is a separate track worth discussing with a provider if levels stay low despite weight loss.
What about muscle loss?
Roughly 20-30% of the weight lost on GLP-1 medications is lean muscle mass, not fat – a ratio that appears broadly similar for men and women, though tirzepatide has shown somewhat greater lean-mass decline than semaglutide in recent body-composition research. That’s still an improvement over unassisted dieting, where lean mass can account for 40-50% of total weight lost.
For men specifically, protecting muscle matters because more baseline muscle mass means more absolute muscle at risk. Two things make the biggest difference:
- Eating roughly 0.8-1.0 grams of protein per pound of current body weight daily
- Doing resistance training at least 2-3 times a week throughout treatment
Skipping both doesn’t just cost strength – it can slow metabolic rate and make the weight harder to keep off later.
Semaglutide vs tirzepatide: which works better for men?
The pattern that holds for the general population holds for men too: tirzepatide edges out semaglutide. Head-to-head trial data shows tirzepatide produces greater average weight loss at comparable time points, largely because it acts on two gut hormone pathways (GLP-1 and GIP) instead of one. See what dose of Zepbound is most effective for a full dose-by-dose breakdown.
Neither drug is universally “better” for every man – tolerability, cost, and insurance coverage often decide which one someone actually sticks with, and sticking with treatment matters more than a percentage-point edge on paper.
The bottom line
Weight loss injections work the same way in men’s bodies as in women’s, at the same doses – but men should expect to lose a smaller percentage of body weight, often more pounds in absolute terms, and see testosterone move in a favorable direction as fat mass comes down. Pairing treatment with protein intake and resistance training protects the muscle that’s most worth keeping.
Curious which medication and dose fits your situation? Talk to a Heally provider about weight loss prescriptions.
FAQ
Do men need a higher dose of semaglutide or tirzepatide than women?
No. Dose escalation is based on individual tolerability and response, not sex. Men and women follow the same titration schedule for both drugs.
Why do men lose weight slower than women on the same medication?
Research points to estrogen amplifying GLP-1’s effect on the brain’s appetite centers. Without that hormonal boost, men typically see a smaller percentage reduction in body weight, though the biological response is still real and clinically meaningful.
Can weight loss injections raise testosterone in men?
They can, indirectly. A 2025 study found testosterone normalized in significantly more men after 18 months of GLP-1 treatment, likely because losing fat mass reduces the inflammation and hormone conversion that suppress testosterone in the first place.
Do men lose more muscle than women on GLP-1 drugs?
The proportion of lean mass lost – roughly 20-30% of total weight lost – appears similar between sexes. Because men typically carry more muscle mass to begin with, protecting it with protein and resistance training is especially worthwhile.
Is tirzepatide or semaglutide better for men?
Tirzepatide tends to produce greater average weight loss in head-to-head studies, for men and women alike. The right choice still depends on tolerability, cost, and what a person can stay consistent with long-term.
Sources
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1). New England Journal of Medicine, 2021.
- Davies M, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes” (STEP 2). The Lancet, 2021.
- Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance” (STEP 4). JAMA, 2021.
- Oxford Academic, Endocrinology. “GLP-1 and Its Analogs: Does Sex Matter?” 2025. academic.oup.com
- Endocrine Society, ENDO 2025 Annual Meeting. Retrospective analysis, 110 men, testosterone normalization on GLP-1 therapy.
- Neeland IJ, et al. “Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.” Diabetes, Obesity and Metabolism, 2024.
- Research Square / medRxiv. “Greater lean-body-mass decline with tirzepatide than semaglutide in routine care.” 2026.
This article is for informational purposes and isn’t a substitute for personalized medical advice. Talk to a licensed provider before starting or changing any weight loss medication.